SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020
Clinical and economic impact of medication reconciliation in cancer patients: a systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence of medication-related problems and its predictors among cancer patients in Ethiopia: A systematic review and meta-analysis.PloS one · 2026Pooled it
- Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review.Journal of cancer research and clinical oncology · 2023Pooled it
- Does drug dispensing improve the health outcomes of patients attending community pharmacies? A systematic review.BMC health services research · 2021Pooled it
- Clinical and Economic Outcomes of Korea's National Polypharmacy Management Program for Hospitalized Older Adults: 90-Day Readmission and Healthcare Costs.Drugs & aging · 2026Article
- Comparison of Patient-Reported Hospital Discharge Experiences in Patients with Long-Term and Episodic Opioid Therapy: A Qualitative Study.Journal of general internal medicine · 2026Article
- Review
- Impact of clinical pharmacist involvement on emergency department physicians' work-time distribution: a comparative analysis.Therapeutic advances in drug safety · 2025Article
- Article
- Discussion on the optimization of personalized medication using information systems based on pharmacogenomics: an example using colorectal cancer.Frontiers in pharmacology · 2024Review
- Characterizing Current and Optimal Involvement of Hospital Pharmacists in the Discharge Process: A Survey of Pharmacists in British Columbia.The Canadian journal of hospital pharmacy · 2024Article
- Ovarian cancer in the older patient: where are we now? What to do next?Therapeutic advances in medical oncology · 2023Review
- Readmission rates and predictors of avoidable readmissions in older adults in a tertiary care centre.Journal of family medicine and primary care · 2022Article
- Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.Cancers · 2022Review
- Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases.Journal of cancer research and clinical oncology · 2022Article
- Insights into British Columbian Hospital Pharmacists Perspectives on the Discharge Process.Innovations in pharmacy · 2022Article
- Importance of medication reconciliation in cancer patients.Journal of pharmaceutical policy and practice · 2021Article
- Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective.Frontiers in oncology · 2021Article
- Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).Cancer treatment reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMedication reconciliation can reduce drug-related iatrogenesis by facilitating exhaustive information transmission at care transition points. Given the vulnerability of cancer patients to adverse drug events, medication reconciliation could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on medication reconciliation in cancer patients.
methodsA comprehensive search was performed in the PubMed/Medline, Scopus, and Web of Science databases, associating the keywords "medication reconciliation" and "cancer" or "oncology."
resultsFourteen studies met the selection criteria. Various medication reconciliation practices were reported: performed at admission or discharge, for hospitalized or ambulatory patients treated with oral or parenteral anticancer drugs. In one randomized controlled trial, medication reconciliation decreased clinically significant medication errors by 26%. Although most studies were non-comparative, they highlighted that medication reconciliation led to identification of discrepancies and other drug-related problems in up to 88% and 94.7% of patients, respectively. The impact on post-discharge healthcare utilization remains under-evaluated and mostly inconclusive, despite a trend toward reduction. No comparative economic evaluations were available but one study estimated the benefit:cost ratio of medication reconciliation to be 2.31:1, suggesting its benefits largely outweigh its costs. Several studies also underlined the extended pharmacist time required for the intervention, highlighting the need for further cost analysis.
conclusionMedication reconciliation can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.
Indexed as
Identifiers
32189099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.